Arcturus Therapeutics Faces $0.92 EPS Loss Forecast, Citi Cuts Target to $7
Arcturus Therapeutics will report Q4 2025 results on March 3, with analysts forecasting a $0.92 per share loss and $14.37 million in revenues, down 36.9% from year-ago. Citi reduced its price target to $7 and highlighted near-term CF inhaled mRNA Phase 2b milestones and FDA OTC discussions.
1. Q4 2025 Earnings Preview
Arcturus Therapeutics is scheduled to release its fourth quarter and full year 2025 financial results on March 3, with consensus forecasts calling for a $0.92 per share loss and $14.37 million in revenues, representing a 17.1% year-over-year increase in loss and a 36.9% drop in sales.
2. Citi Lowers Price Target
Citi analysts trimmed the company’s price target to $7 from prior levels, citing pipeline valuation concerns and the near-term revenue gap ahead of the earnings report.
3. Inhaled mRNA CF Program Updates
Management has mapped near-term milestones for its inhaled mRNA cystic fibrosis candidate entering Phase 2b and is engaged in FDA discussions on an over-the-counter development program, which could influence clinical timelines and future partnerships.